News – Page 31 – Alligator Bioscience

2021-09-30

Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer

Lund, Sweden, September 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that it has dosed the first patient in it ...

2021-09-22

Alligator to Participate in Upcoming Investor Conferences

Lund, Sweden, September 23, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that Søren Bregenholt, Chief Execu ...

2021-09-02

Regulatory

Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...

2021-09-02

Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX) and Scandion Oncology A/S (Nasdaq Stockholm: SCOL), toda ...

2021-08-18

Regulatory

Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation

Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...

2021-08-16

Alligator Bioscience Announces New Senior Director of Communications & Investor Relations

Lund, Sweden, August 16, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Julie Silber has joined the company as t ...

2021-07-13

Regulatory

Alligator Bioscience AB: Interim report January–June 2021

Positive Phase I data for ATOR-1017 ”As new CEO of Alligator Bioscience, after just around a month, let me say that my high expectations on ...

2021-06-30

Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data

Lund, Sweden, June 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Nasdaq Stockholm: SCOL) today announces ...

2021-06-07

Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy

Lund, Sweden, June 7, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the scientific journal Expert Opinion on Bi ...